Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Clinical evidence

RAPIDe-1

92 evidence topics · 15 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using change in the 3-Symptom composite visual analogue scale score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Registry participant flow by randomized dose cohort, Part I and Part II
MilestoneDeucrictibant 10 mg cohortDeucrictibant 20 mg cohortDeucrictibant 30 mg cohort
Part I started“24”“25”“25”
Part I completed“24”“24”“25”
Part I withdrawal by subject“0”“1”“0”
Part II started“24”“24”“25”
Part II completed“16”“12”“12”
Part II not completed“8”“12”“13”
Part II withdrawal by subject“2”“3”“5”
Part II not completed: “Participants Met Primary Analysis Criteria”“6”“9”“8”
Baseline characteristics
Demographics and HAE characteristics by dose cohort, full analysis set
CharacteristicDeucrictibant 10 mg (n=24)Deucrictibant 20 mg (n=25)Deucrictibant 30 mg (n=25)
Age, years, median (IQR)“44 (31–53)”“45 (36–57)”“39 (25–53)”
Female, n (%)“17 (71%)”“17 (68%)”“15 (60%)”
White, n (%)“22 (92%)”“24 (96%)”“25 (100%)”
HAE-C1INH type 1, n (%)“19 (79%)”“22 (88%)”“24 (96%)”
HAE-C1INH type 2, n (%)“5 (21%)”“2 (8%)”“1 (4%)”
Time since diagnosis, years, median (IQR)“18 (10–26)”“21 (13–37)”“23 (10–37)”
More than 4 attacks in the 4 months before screening, n (%)“20 (83%)”“20 (80%)”“20 (80%)”
Long-term prophylactic treatment history, n (%)“3 (13%)”“5 (20%)”“5 (20%)”
Registry baseline age and ethnicity, full analysis set
CharacteristicDeucrictibant 10 mgDeucrictibant 20 mgDeucrictibant 30 mgTotal
Participants“24”“25”“25”“74”
Age, years, mean (SD)“42.9”( “14.15”)“45.7”( “13.89”)“41.4”( “15.38”)“43.3”( “14.41”)
Aged 65 to 84 years“2”“1”“2”“5”
Hispanic or Latino“3”“2”“0”“5”
Efficacy results
Primary endpoint: change in VAS-3 at 4 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set of 147 attacks in 62 participants
MeasureDeucrictibant 10 mg (n=21)Deucrictibant 20 mg (n=16)Deucrictibant 30 mg (n=20)Placebo (n=51)
Attacks with VAS-3 at 4 h“33”“27”“30”“43”
VAS-3 at 4 h, mean (SD)“12·09 (14·47)”“11·93 (9·97)”“14·71 (10·51)”“30·09 (18·20)”
LSM difference vs placebo (95% CI)“−16·75 (−21·52 to −11·97)”“−15·02 (−20·22 to −9·81)”“−16·28 (−21·27 to −11·29)”Not applicable
p valueNot reported“<0·0001”“<0·0001”Not applicable
Primary endpoint: registry least squares mean change and nominal p value for 10 mg, participants with evaluable data
GroupParticipantsLS mean change in VAS-3 (SE)LS mean difference vs placebo (95% CI)p value
Deucrictibant 10 mg“21”“-14.83”( “1.833”)“-16.75”( “-21.52”to “-11.97”)“< 0.0001”, “Nominal p-value”
Deucrictibant 20 mg“16”“-13.10”( “2.111”)“-15.02”( “-20.22”to “-9.81”)“< 0.0001”
Deucrictibant 30 mg“20”“-14.37”( “1.975”)“-16.28”( “-21.27”to “-11.29”)“< 0.0001”
Placebo“51”“1.92”( “1.596”)Not applicableNot applicable
Key secondary endpoints: time to symptom relief, 50% reduction, and resolution by VAS-3, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set
Endpoint and measureDeucrictibant 10 mg (37 attacks)Deucrictibant 20 mg (28 attacks)Deucrictibant 30 mg (31 attacks)Placebo (51 attacks)
Onset of symptom relief (≥30% VAS-3 reduction), median h (95% CI)“2·1 (1·5 to 2·9)”“2·7 (1·9 to 3·5)”“2·5 (1·9 to 3·8)”“8·0 (7·6 to NE)”
Onset of symptom relief, hazard ratio (95% CI)“3·81 (2·01 to 7·20)”“3·08 (1·50 to 6·30)”“3·61 (2·10 to 6·19)”Not applicable
Onset of symptom relief, p valueNot reported“0·0021”“<0·0001”Not applicable
≥50% VAS-3 reduction, median h (95% CI)“3·3 (2·4 to 3·9)”“4·0 (2·9 to 6·0)”“4·0 (3·3 to 5·8)”“22·8 (20·0 to 24·1)”
≥50% VAS-3 reduction, hazard ratio (95% CI)“4·55 (2·41 to 8·59)”“3·65 (1·80 to 7·38)”“3·87 (2·26 to 6·63)”Not applicable
≥50% VAS-3 reduction, p valueNot reported“0·0003”“<0·0001”Not applicable
Almost complete or complete symptom relief, median h (95% CI)“5·8 (3·6 to 7·5)”“20·0 (4·5 to 20·0)”“20·0 (6·0 to 20·1)”“42·0 (22·0 to NE)”
Almost complete or complete symptom relief, hazard ratio (95% CI)“5·09 (2·81 to 9·22)”“2·25 (1·19 to 4·27)”“2·65 (1·61 to 4·38)”Not applicable
Almost complete or complete symptom relief, p valueNot reported“0·013”“<0·0001”Not applicable
Key secondary endpoints: change in MSCS score and TOS at 4 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set
Endpoint and measureDeucrictibant 10 mgDeucrictibant 20 mgDeucrictibant 30 mgPlacebo
MSCS, attacks“32”“26”“27”“40”
MSCS, mean change from pre-treatment (SD)“−1·08 (0·13)”“−0·91 (0·14)”“−0·68 (0·14)”“−0·29 (0·11)”
MSCS, LSM difference vs placebo (95% CI)“−0·79 (−1·11 to −0·46)”“−0·61 (−0·97 to −0·26)”“−0·39 (−0·73 to −0·04)”Not applicable
MSCS, p valueNot reported“0·0008”“0·029”Not applicable
TOS, attacks“32”“25”“28”“40”
TOS, mean (SD) score“57·03 (58·63)”“62·67 (36·09)”“68·75 (38·86)”“−2·71 (62·49)”
TOS, LSM difference vs placebo (95% CI)“64·13 (40·35 to 87·91)”“62·69 (36·71 to 88·67)”“71·06 (46·09 to 96·03)”Not applicable
TOS, p valueNot reported“<0·0001”“<0·0001”Not applicable
Rescue medication use within 12, 24, and 48 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set
Window and measureDeucrictibant 10 mgDeucrictibant 20 mgDeucrictibant 30 mgPlacebo
Within 12 h, attacks with rescue medication, n (%)“7 (19%)”“3 (11%)”“2 (7%)”“31 (61%)”
Within 12 h, OR vs placebo (95% CI)“0·15 (0·06 to 0·37)”“0·08 (0·02 to 0·35)”“0·04 (0·01 to 0·18)”Not applicable
Within 24 h, attacks with rescue medication, n (%)“9 (24%)”“3 (11%)”“4 (13%)”“37 (73%)”
Within 24 h, OR vs placebo (95% CI)“0·12 (0·05 to 0·29)”“0·05 (0·01 to 0·19)”“0·06 (0·02 to 0·18)”Not applicable
Within 48 h, attacks with rescue medication, n (%)“9 (24%)”“4 (14%)”“5 (16%)”“37 (73%)”
Within 48 h, OR vs placebo (95% CI)“0·12 (0·05 to 0·29)”“0·07 (0·02 to 0·24)”“0·07 (0·02 to 0·22)”Not applicable
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events within 5 days by part and dose, safety analysis set
EventPart 1, 10 mg (n=23)Part 1, 20 mg (n=24)Part 1, 30 mg (n=25)Part 2, 10 mg (38 attacks; n'=21)Part 2, 20 mg (29 attacks; n'=16)Part 2, 30 mg (36 attacks; n'=22)Part 2, placebo (53 attacks; n'=53)
Any treatment-emergent adverse event“2 (9%)”“2 (8%)”“4 (16%)”“3 (8%)”, “3 (14%)”“1 (3%)”, “1 (6%)”“2 (6%)”, “2 (9%)”“3 (6%)”, “3 (6%)”
Any treatment-related treatment-emergent adverse event“1 (4%)”“1 (4%)”“0”“0”“0”“1 (3%)”, “1 (5%)”“1 (2%)”, “1 (2%)”
Registry adverse event counts by part and treatment group
Event groupDeathsSerious adverse eventsOther adverse events
Part I, 10 mg (participants)“0”of “23”“0”of “23”“2”of “23”
Part I, 20 mg (participants)“0”of “24”“0”of “24”“2”of “24”
Part I, 30 mg (participants)“0”of “25”“0”of “25”“4”of “25”
Part II, 10 mg (study drug treated attacks)“0”of “38”“0”of “38”“3”of “38”
Part II, 20 mg (study drug treated attacks)“0”of “29”“0”of “29”“1”of “29”
Part II, 30 mg (study drug treated attacks)“0”of “36”“0”of “36”“2”of “36”
“Part II Placebo”“0”of “53”“0”of “53”“4”of “53”
Treatment-related adverse events in the top-line data and a congress poster
Study limitations
Summary
  • The authors stated that “Limitations of the RAPIDe-1 trial include the absence of randomisation of attacks according to location and severity”; a higher proportion of attacks primarily in the abdominal area were treated with 10 mg than with other doses or placebo.
  • Attacks with vomiting or involving the internal head or neck, including laryngeal attacks, were excluded from treatment, and “reoccurrence of attack symptoms following treatment was not evaluated as a predefined endpoint”.
  • The population was limited to adults aged 18 to 75 years with hereditary angioedema type 1 or 2 who were not receiving long-term prophylaxis. Patients with abnormal hepatic or renal function, users of moderate or potent CYP3A4 inhibitors or inducers, and pregnant or breastfeeding women were excluded. In the mITT analysis set, 60 (97%) of 62 participants were White.
  • The primary analysis was done before all enrolled participants had treated three attacks; the final analysis of 165 attacks was descriptive. The primary efficacy analysis included 62 of 74 randomized participants, with 28 to 37 attacks per deucrictibant dose. In the registry participant flow, Part II was completed by 16 of 24, 12 of 24, and 12 of 25 participants in the 10 mg, 20 mg, and 30 mg cohorts.
  • The 10 mg group had no multiplicity control and was analysed descriptively. The registry notes that within-participant correlation was not accounted for in the Kaplan-Meier medians. End of progression and outcomes by attack location were post-hoc analyses.
  • TSQM and other lower-ranked secondary endpoints are to be reported elsewhere. In August 2022 the FDA placed US trials on clinical hold, and only 2 remaining US participants were permitted to complete treatment of a final attack.